HIGH-DOSE METHOTREXATE WITH LEUCOVORIN RESCUE, VINBLASTINE, AND BLEOMYCIN WITH OR WITHOUT TAMOXIFEN IN METASTATIC RENAL-CELL CARCINOMA
- 1 January 1984
- journal article
- research article
- Vol. 68 (4) , 587-590
Abstract
A regimen of high-dose methotrexate with leucovorin rescue, vinblastine and bleomycin with or without tamoxifen was administered to 34 patients with metastatic renal cell carcinoma. No complete remissions were observed, but 10 patients (30%) achieved partial remission and an additional 13 patients (39%) had stabilization of disease. The median survival of responding patients (110 wk) was significantly longer than that of nonresponding patients. The addition of tamoxifen did not influence response or survival. This regimen was tolerated without significant toxicity. A prospective randomized study of the vinblastine and high-dose methotrexate regimen compared to the respective single agents seem to be indicated.This publication has 4 references indexed in Scilit:
- METHOTREXATE-CITROVORUM FACTOR USED ALONE AND IN COMBINATION CHEMOTHERAPY FOR ADVANCED HYPERNEPHROMAS1980
- The clinical pharmacology of methotrexate.new applications of an old drugCancer, 1978
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- SINGLE-AGENT THERAPY FOR RENAL CELL-CARCINOMA - CCNU, VINBLASTINE, THIOTEPA, OR BLEOMYCIN1977